Multiple Myeloma News
Salvage Therapy for Amyloidosis in Multiple Myeloma: Agents and Anti-Fibril Therapy
Source: Pharmacy Times articles A presentation at the Society of Hematologic Oncology 2021 Annual Meeting reviewed the treatment of amyloidosis in multiple myeloma. Read More
Myeloma research on the move
Source: Myeloma : nature.com subject feeds Post Content Read More
Updates in Sequencing Treatment for Early Multiple Myeloma Relapse
Source: Pharmacy Times articles Presenter Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca-IBSAL, Salamanca, Spain, discussed how optimal sequencing in MM has changed from those outlined in the older EU guidelines. Read More
Dosing Schedule of Intravenous Bisphosphonate Has Little Effect on Recurrent Skeletal-Related Events in Patients With Multiple Myeloma
Source: Myeloma – Hematology Advisor Fewer administrations of intravenous bisphosphonate among patients with multiple myeloma had comparable rates of recurrent skeletal-related events (SRE) compared with more frequent dosing. These findings, from a retrospective...
Prognostic Importance of Extramedullary Lesions in Multiple Myeloma
Source: Myeloma – Hematology Advisor Researchers conducting a retrospective study identified extramedullary (EM) lesions as a possible indicator of poor prognosis in patients with multiple myeloma (MM) treated in the first line with bortezomib. The study’s results...
Patients With Multiple Myeloma, Shortest Survival Times Have the Most Kidney Damage
Source: Pharmacy Times articles Nearly 20% of patients with multiple myeloma have a form of the disease in which they make high quantities of a component of monoclonal proteins, which damages the kidneys. Read More
Machine Learning Algorithm May Predict Treatment Sensitivity in Multiple Myeloma
Source: Myeloma – Hematology Advisor A machine learning algorithm may help to improve first-line treatment decisions in up to 17% of patients diagnosed with multiple myeloma (MM), according to a paper published in PLoS One. MM is an incurable hematologic cancer with a...
Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition
Source: Myeloma : nature.com subject feeds Post Content Read More
Analyzing Minimal Residual Disease for Patients With Multiple Myeloma
Source: Myeloma – Hematology Advisor Targeted and immune therapies to treat multiple myeloma (MM) are advancing rapidly, and minimal residual disease (MRD) negativity is possible across the disease spectrum. MRD may be a surrogate endpoint for patient outcomes in...
A Case of Multiple Myeloma Presenting With Ophthalmic Changes
Source: Myeloma – Hematology Advisor Researchers in Brazil presented a case report in the journal Case Reports in Ophthalmology of a patient with multiple myeloma (MM) who developed immunogammopathy maculopathy and hyperviscosity syndrome (HVS)-related retinopathy....